DOI: https://doi.org/10.15587/2313-8416.2015.50513

Prognostic markers of efficiency of immunosupressive therapy in patients with myelodysplastic syndrome

Ольга Ігорівна Бойко, Звенислава Володимирівна Масляк, Звенислава Володимирівна Масляк, Ярослава Іллівна Виговська, Ярослава Іллівна Виговська, Мар’яна Іванівна Сімонова, Мар’яна Іванівна Сімонова, Наталія Яремівна Томашевська, Наталія Яремівна Томашевська

Abstract


Introduction: There is no “gold standard” of the treatment of myelodysplastic synfrom (MDS) for today. Use of the different directions of therapy at MDS is caused by the prognosis of clinical course, age and general state of patient, donor presence and possibility for an adequate attendant therapy. That is why the search of standards of treatment at MDS continues

Aim: To analyze an efficiency of the therapy with cyclosporine A in patients with MDS of the low risk and to detect the new prognostic factors of response to treatment.

Methods: 25 patients with MDS RA were examined according to FAB-classification, 15 women and 10 men whose mean age was 55 years. Statistical analysis of material was carried out using packages of applications STATISTICA for Windows 5,0 and NCSS. Parametric indicators were described as a median [lower-upper quartile] (minimum-maximum). The dynamics of parametric indicators in every group was assessed using Wilcoxon criterion.

Results: During the treatment with cyclosporine A the complete clinical and hematological remission was received in 28 % of patients, the partial remission was fixed in 25 % of patients and hematological improvement according to criteria of the system of International working group (IWG) – in 28 % of treated patients. It was revealed the reliable decrease of TNF-α, TGF-β and IL-6 in the process of treatment that prove the target mechanism of an effect of preparation at myelodysplastic syndrome. An influence of cytokines on the probability of positive result of treatment was not confirmed. It was established that the young age of patients, hypo- or normocellular marrow, an increased rate of lymphocytes in myelogram, an absence of hemotransfusion dependence and the level of hemoglobin higher than 80 g/l cause the better response to treatment with cyclosporine A. TNF-a concentration higher than 8 mg|ml is a marker of an early relapse in patients treated with cyclosporine A


Keywords


myelodysplastic syndrome; cyclosporine A; cytokine; marrow

References


Greenberg, P. L., Stone, R. M., Bejar, R., Bennett, J. M., Bloomfield, C. D., Borate, U. et. al (2015). Myelodysplastic Syndromes, Version 2.2015. Featured updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 13 (3), 261–272.

Kastrinaki, M.-C., Pavlaki, K., Batsali, A. K., Kouvidi, E., Mavroudi, I., Pontikoglou, C., & Papadaki, H. A. (2013). Mesenchymal Stem Cells in Immune-Mediated Bone Marrow Failure Syndromes. Clinical and Developmental Immunology, 2013, 1–10. doi: 10.1155/2013/265608

Tomashevska, N. J., Vigovs’ka, J. I., Masliak, Z. V. (2007). Rol’ cytokiniv u patogenezi mielodysplastichnogo sindromu [The role of cytokines in the pathogenesis of Myelodysplastic Syndrome]. Ukrainckii zurnal hematologii I transfuziologii. Ukrainian journal of Haematology and transfusiology, 9 (2), 95–100.

Boehrer, S. (2008). Pathogenesis and targets in Myelodysplastic syndromes. Hematology (EHA Educ. Program), 76–82.

Barrett, A. J., Sloand, E. (2009). Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica, 94 (4), 449–451. doi: 10.3324/haematol.2009.006080

Skvorcov, V. V., Tumarenko, A. V., Skvorcov, E. M. (2009). Mielodisplastichni sindromi [Myelodysplastic syndromes]. Terapevticheskii arhiv. Therapeutic Archive, 8, 32–37.

Kasner, M. T., Luger, S. M. (2009). Update on the therapy for myelodysplastic syndrome. American Journal of Hematology, 84 (3), 177–186. doi: 10.1002/ajh.21352

Aggarwal, S., van de Loosdrecht, A. A., Alhan, C., Ossenkoppele, G. J., Westers, T. M., Bontkes, H. J. (2011). Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. British Journal of Haematology, 153 (5), 568–581. doi: 10.1111/j.1365-2141.2011.08683.x

Risitano, A. M. (2010). Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. British Journal of Haematology, 152 (2), 127–140. doi: 10.1111/j.1365-2141.2010.08439.x

Malcovati, L., Hellstrom-Lindberg, E., Bowen, D. et. al (2013). Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 122 (17), 2943–2964. doi: 10.1182/blood-2013-03-492884

Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., Barrett, J. (2008). Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy. Journal of Clinical Oncology, 26 (15), 2505–2511. doi: 10.1200/jco.2007.11.9214


GOST Style Citations


1. Greenberg, P. L. Myelodysplastic Syndromes, Version 2.2015. Featured updates to the NCCN Guidelines [Тext] / P. L. Greenberg, R. M. Stone, R. Bejar, J. M. Bennett, C. D. Bloomfield, U. Borate et. al // JNCCN Journal of the National Comprehensive Cancer Network. − 2015. – Vol. 13, Issue 3. − P. 261–272.

2. Kastrinaki, M.-C. Mesenchymal Stem Cells in Immune-Mediated Bone Marrow Failure Syndromes [Тext] / M.-C. Kastrinaki, K. Pavlaki, A. K. Batsali, E. Kouvidi, I. Mavroudi, C. Pontikoglou, H. A. Papadaki // Clinical and Development Immunology. – 2013. − P. 1–10. doi: 10.1155/2013/265608

3. Томашевська, Н. Я. Роль цитокінів у патогенезі мієлодиспластичного синдрому [Текст] / Н. Я. Томашевська, Я. І. Виговська, З. В. Масляк // Укр журнал гематології та трансфузіології. − 2007. – Т. 9, № 2. − С. 95–100.

4. Boehrer, S. Pathogenesis and targets in Myelodysplastic syndromes [Тext] / S. Boehrer // Hematology (EHA Educ. Program). − 2008. − P. 76–82.

5. Barret, A. J. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance [Тext] / A. J. Barret, E. Sloand // Heamatologica. − 2009. – Vol. 94, Issue 4. − P. 449–451. doi: 10.3324/haematol.2009.006080

6. Скворцов В. В. Миєлодиспластические синдромы [Текст] / В. В. Скворцов, А. В. Тумаренко, Е. М. Скворцова // Терапевт. Архив. – 2009. – № 8. – С. 32–37.

7. Kasner, M. T. Update on the therapy for myelodysplastic syndrome [Тext] / M. T. Kasner, S. M. Luger // American Journal of Hematology. − 2009. – Vol. 84, Issue 3. – P. 177–186. doi: 10.1002/ajh.21352

8. Aggarwal, S. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implication for immunotherapy [Тext] / S. Aggarwal, A. A. van de Loosdrecht, C. Alhan, G. J. Ossenkoppele, T. M. Westers, H. J. Bontkes // British Journal of Haematology. − 2011. − Vol. 153, Issue 5. − P. 568–581. doi: 10.1111/j.1365-2141.2011.08683.x

9. Risinato, A. M. Immunosuppressive therapies in the managments of immune-mediated marrov failures in adults-where we stand and where we are going [Тext] /A. M. Risinato // British Journal of Haematology. − 2011. − Vol. 152, Issue 2. − P. 127–140. doi: 10.1111/j.1365-2141.2010.08439.x

10. Malcovati, L. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European Leukemia Net [Тext] / L. Malcovati, E. Hellstrom-Linberg, D. Bowen et. al // Blood. − 2013. − Vol.122, Issue 17. – P. 2943–2964. doi: 10.1182/blood-2013-03-492884

11. Sloand, E. M. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy [Тext] / E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, J. Barrett // Journal of Clinical Oncology. − 2008. – Vol. 26, Issue 15. − P. 2505–2511. doi: 10.1200/jco.2007.11.9214







Copyright (c) 2015 Ольга Ігорівна Бойко, Звенислава Володимирівна Масляк, Звенислава Володимирівна Масляк, Ярослава Іллівна Виговська, Ярослава Іллівна Виговська, Мар’яна Іванівна Сімонова, Мар’яна Іванівна Сімонова, Наталія Яремівна Томашевська, Наталія Яремівна Томашевська

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2313-8416 (Online), ISSN 2313-6286 (Print)